Matthew Dankner
Institut du cancer Rosalind & Morris Goodman · 101 works · 2,087 citations · h-index 19
Top works
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
- Neoadjuvant Chemoimmunotherapy for NSCLC
- Single-cell spatial immune landscapes of primary and metastatic brain tumours
- Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
- Spatially mapping the immune landscape of melanoma using imaging mass cytometry
- CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy
- The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
- DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
- Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
- STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer
- Non-small-cell lung cancer: how to manage BRAF-mutated disease
- The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers
- Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases
- The role of CRAF in cancer progression: from molecular mechanisms to precision therapies
- Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology
- Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors
- Gender Disparities in Academic Outcomes Among Graduates of a Canadian MD-PhD Program
- Radiomics as an emerging tool in the management of brain metastases
- Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
- Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases